Clinical trials located in


Søborg city is located in Denmark. Currently, 6 clinical trials are being conducted in this city.

Søborg, nestled in Denmark, is a city with a rich tapestry of history and modernity. Originating from medieval times, it is home to the ruins of Søborg Castle, once a formidable fortress in the 12th century. Today, Søborg thrives as a suburban area of Copenhagen, blending its historical roots with contemporary Danish life. The city is known for its vibrant community, green spaces, and as a hub for businesses. Its proximity to Copenhagen allows for a unique mix of urban convenience and serene landscapes, making Søborg a notable city in Denmark’s cultural and economic landscape.

  • CT-EU-00084523

    Testing a new medicine for diabetes and weight loss

    This study tests NNC0519-0130, a new medicine, possibly help people with type 2 diabetes or high body weight by reducing blood sugar levels and appetite. The trial will check how safe the medicine is and how it affects the body, including blood sugar, fat levels, and weight. Participants, both healthy and with diabetes, will receive the medicine or a placebo through injections or orally. The study aims to find the right doses and understand the medicine’s effects over several weeks.

    • NNC0519-0130- new medication for type 2 diabetes
  • A study comparing different vaccine doses in older people

    This study is on the flu vaccine, and it’s specifically for older adults. The researchers want to see whether giving a higher dose of the flu vaccine is more effective than the usual dose. To accomplish this, researchers are going to split the participants into two groups. One group will get the high-dose vaccine and the other group will get the standard one. This is called a randomized trial. Researchers will use health records to collect information about the participants, like their health before the study and any side effects they might have during the study.

    • Quadrivalent Influenza Vaccine
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Denmark: